Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 4-sequence, Cross-over, Double-blind, Dose Response Study of 0.4, 0.6 and 0.9 U/kg Insulin Glargine U300 Compared to 0.4 U/kg Lantus U100 in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique.

Next Previous
Search
Trial Profile

A Randomized, 4-sequence, Cross-over, Double-blind, Dose Response Study of 0.4, 0.6 and 0.9 U/kg Insulin Glargine U300 Compared to 0.4 U/kg Lantus U100 in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 18 Jun 2013 Results presented at American Diabetes Association (ADA) 73rd Scientific Sessions, according to a Sanofi media release.
    • 13 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top